Current status and prospects for development of a vaccine against Trichomonas vaginalis infections

Vaccine

Volumn 32, Issue 14, 2014, Pages 1588-1594

  Smith, Jeffrey ^a   Garber, Gary E ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

HIV susceptibility; Immune response; Trichomonas vaginalis; Vaccine development; Vaginitis

Indexed keywords

ALUMINUM HYDROXIDE; FREUND ADJUVANT; GALECTIN 1; LIPOPHOSPHOGLYCAN; METRONIDAZOLE; TINIDAZOLE; TRICHOMONIASIS VACCINE; WART VIRUS VACCINE;

ANTIFUNGAL RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INCIDENCE; MATERNAL WELFARE; MURINE MODEL; NONHUMAN; PARASITE EXAMINATION; PARASITE TRANSMISSION; POLYMERASE CHAIN REACTION; PREGNANCY; PREVALENCE; PRIMATE MODEL; PRIORITY JOURNAL; RAPID TEST; SEXUALLY TRANSMITTED DISEASE; TRANSCRIPTION MEDIATED AMPLIFICATION; TRICHOMONAS RAPID TEST; TRICHOMONIASIS; TRITRICHOMONAS FOETUS; TRITRICHOMONAS FOETUS INFECTION; URINALYSIS; VACCINATION; VIRUS TRANSMISSION;

HIV SUSCEPTIBILITY; IMMUNE RESPONSE; TRICHOMONAS VAGINALIS; VACCINE DEVELOPMENT; VAGINITIS;

ANIMALS; FEMALE; HIV INFECTIONS; HUMANS; MALE; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS; VACCINATION; VACCINES;

EID: 84896709728     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.050     Document Type: Article

References (77)

1. World Health Organization Prevalence and incidence of selected sexually transmitted infections. Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates 2011, WHO, Geneva, Switzerland.
2. World Health Organization Global incidence and prevalence of selected curable sexually transmitted infections - 2008 2012, WHO, Geneva, Switzerland.
3. Hesseltine H.C., Wolters S., Campbell A. Experimental human vaginal trichomoniasis. Journal of Infectious Diseases 1942, 127-130.
4. Pastorek I.I., Cotch J.G., Martin M.F., Eschenbach D.H.D.A. Clinical and microbiological correlates of vaginal trichomoniasis during pregnancy. Clinical Infectious Diseases 1996, 23(5):1075-1080.
5. Seña A.C., Miller W.C., Hobbs M.M., Schwebke J.R., Leone P.A., Swygard H., et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2007, 44(1):13.
6. Wølner-Hanssen P., Krieger J.N., Stevens C.E., Kiviat N.B., Koutsky L., Critchlow C., et al. Clinical manifestations of vaginal trichomoniasis. The Journal of the American Medical Association 1989, 261(4):571-576.
7. Fichorova R.N. Impact of T. vaginalis infection on innate immune responses and reproductive outcome. Journal of Reproductive Immunology 2009, 83(1):185-189.
8. Kissinger P., Amedee A., Clark R.A., Dumestre J., Theall K.P., Myers L., et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sexually Transmitted Diseases 2009, 36(1):11-16.
9. Moodley P., Wilkinson D., Connolly C., Moodley J., Sturm A.W. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clinical Infectious Diseases 2002, 34(4):519-522.
10. Van Der Pol B., Kwok C., Pierre-Louis B., Rinaldi A., Salata R.A., Chen P., et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. Journal of Infectious Diseases 2008, 197(4):548-554.
11. Zhang Z., Graham S., Yu S., Marshall J., Zielezny M., Chen Y., et al. Trichomonas vaginalis and cervical cancer: a prospective study in China. Annals of Epidemiology 1995, 5(4):325-332.
12. Krieger J.N. Trichomoniasis in men: old issues and new data. Sexually Transmitted Diseases 1995, 22(2):83.
13. Krieger J.N., Jenny C., Verdon M., Siegel N., Springwater R., Critchlow C.W., et al. Clinical manifestations of trichomoniasis in men. Annals of Internal Medicine 1993, 118(11):844.
14. Hobbs M.M., Lapple D.M., Lawing L.F., Schwebke J.R., Cohen M.S., Swygard H., et al. Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. Journal of Clinical Microbiology 2006, 44(11):3994-3999.
15. Schwebke J.R., Hook E.W. High rates of Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: implications for screening and urethritis management. Journal of Infectious Diseases 2003, 188(3):465-468.
16. Brill J.R. Diagnosis and treatment of urethritis in men. American Family Physician 2010, 81(7):873-878.
17. Weston T., Nicol C. Natural history of trichomonal infection in males. British Journal of Venereal Diseases 1963, 39(4):251.
18. Mitteregger D., Aberle S.W., Makristathis A., Walochnik J., Brozek W., Marberger M., et al. High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissue. Medical Microbiology and Immunology 2012, 201(1):113-116.
19. Cotch M.F., Pastorek I.I., Nugent J.G., Hillier R.P., Gibbs S.L., Martin R.S.D.H., et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sexually Transmitted Diseases 1997, 24(6):353-360.
20. Draper D., Jones W., Heine R.P., Beutz M., French J.I., McGregor M., et al. Trichomonas vaginalis weakens human amniochorion in an in vitro model of premature membrane rupture. Infectious Diseases in Obstetrics and Gynecology 1995, 2(6):267-274.
21. Draper D., McGregor J., Hall J., Jones W., Beutz M., Heine R., et al. Elevated protease activities in human amnion and chorion correlate with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology 1995, 173(5):1506-1512.
22. Draper D., Donohoe W., Mortimer L., Heine R.P. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. Journal of Infectious Diseases 1998, 178(3):815-819.
23. McNeely T., Dealy M., Dripps D., Orenstein J., Eisenberg S., Wahl S. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. Journal of Clinical Investigation 1995, 96(1):456.
24. Johnston V.J., Mabey D.C. Global epidemiology and control of Trichomonas vaginalis. Current Opinion in Infectious Diseases 2008, 21(1):56-64.
25. Klebanoff M.A., Carey J.C., Hauth J.C., Hillier S.L., Nugent R.P., Thom E.A., et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. New England Journal of Medicine 2001, 345(7):487-493.
26. Mavedzenge S.N., Van Der Pol B., Cheng H., Montgomery E.T., Blanchard K., de Bruyn G., et al. Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sexually Transmitted Diseases 2010, 37(7):460-466.
27. McClelland R.S. Trichomonas vaginalis infection: can we afford to do nothing?. Journal of Infectious Diseases 2008, 197(4):487-489.
28. Quinlivan E.B., Patel S.N., Grodensky C.A., Golin C.E., Tien H., Hobbs M.M. Modeling the impact of Trichomonas vaginalis infection on HIV transmission in HIV-infected individuals in medical care. Sexually Transmitted Diseases 2012, 39(9):671-677.
29. Guenthner P.C., Secor W.E., Dezzutti C.S. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infection and Immunity 2005, 73(7):4155-4160.
30. Thurman A.R., Doncel G.F. Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. American Journal of Reproductive Immunology 2010, 65(2):89-98.
31. Mhlongo S., Magooa P., Müller E.E., Nel N., Radebe F., Wasserman E., et al. Etiology and STI/HIV coinfections among patients with urethral and vaginal discharge syndromes in South Africa. Sexually Transmitted Diseases 2010, 37(9):566-570.
32. de Lemos P.A.P., Garcia-Zapata M.T.A. The prevalence of Trichomonas vaginalis in HIV-positive and negative patients in referral hospitals in Goiania, Goias, Brazil. International Journal of Tropical Medicine 2010, 5(2):24-27.
33. Muzny C.A., Rivers C.A., Austin E.L., Schwebke J.R. Trichomonas vaginalis infection among women receiving gynaecological care at an Alabama HIV Clinic. Sexually Transmitted Infections 2013, February. [Published Online First]. 10.1136/sextrans-2012-050889.
34. Nweze E., Mouneke G. Trichomonas vaginalis in HIV/AIDS subjects in Nigeria. Asian Pacific Journal of Tropical Disease 2011, 1(4):282-286.
35. Anderson B.L., Firnhaber C., Liu T., Swarts A., Siminya M., Ingersoll J., et al. Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sexually Transmitted Diseases 2012, 39(8):638-642.
36. Paz-Bailey G., Sternberg M., Puren A.J., Steele L., Lewis D.A. Determinants of HIV type 1 shedding from genital ulcers among men in South Africa. Clinical Infectious Diseases 2010, 50(7):1060-1067.
37. Wang C.C., McClelland R.S., Reilly M., Overbaugh J., Emery S.R., Mandaliya K., et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. Journal of Infectious Diseases 2001, 183(7):1017-1022.
38. Workowski K.A., Berman S. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR - Recommendations and Reports 2010, 59(RR-12):1-110.
39. Dunne R.L., Dunn L.A., Upcroft P., O'Donoghue P.J., Upcroft J.A. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Research 2003, 13(4):239-249.
40. Kirkcaldy R.D., Augostini P., Asbel L.E., Bernstein K.T., Kerani R.P., Mettenbrink C.J., et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerging Infectious Diseases 2012, 18(6):939.
41. Krashin J.W., Koumans E.H., Bradshaw-Sydnor A.C., Braxton J.R., Secor W.E., Sawyer M.K., et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sexually Transmitted Diseases 2010, 37(7):440-444.
42. Schwebke J.R., Barrientes F.J. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrobial Agents and Chemotherapy 2006, 50(12):4209-4210.
43. Upcroft P., Upcroft J.A. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clinical Microbiology Reviews 2001, 14(1):150-164.
44. Gatski M., Kissinger P. Observation of probable persistent, undetected Trichomonas vaginalis infection among HIV-positive women. Clinical Infectious Diseases 2010, 51(1):114-115.
45. Peterman T.A., Tian L.H., Metcalf C.A., Malotte C.K., Paul S.M., Douglas J.M. Persistent, undetected Trichomonas vaginalis infections?. Clinical Infectious Diseases 2009, 48(2):259-260.
46. Roth A.M., Williams J.A., Ly R., Curd K., Brooks D., Arno J., et al. Changing sexually transmitted infection screening protocol will result in improved case finding for Trichomonas vaginalis among high-risk female populations. Sexually Transmitted Diseases 2011, 38(5):398.
47. Nye M.B., Schwebke J.R., Body B.A. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. American Journal of Obstetrics and Gynecology 2009, 200(2):188e1-188e7.
48. Huppert J.S., Mortensen J.E., Reed J.L., Kahn J.A., Rich K.D., Miller W.C., et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clinical Infectious Diseases 2007, 45(2):194-198.
49. Jones H.E., Lippman S.A., Caiaffa-Filho H.H., Young T., van de Wijgert, Janneke H.H.M. Performance of a rapid self-test for detection of Trichomonas vaginalis in South Africa and Brazil. Journal of Clinical Microbiology 2013, 51(3):1037-1039.
50. Figueroa-Angulo E.E., Rendón-Gandarilla F.J., Puente-Rivera J., Calla-Choque J.S., Cárdenas-Guerra R.E., Ortega-López J., et al. The effects of environmental factors on the virulence of Trichomonas vaginalis. Microbes and Infection 2012.
51. Sehgal R., Goyal K., Sehgal A. Trichomoniasis and lactoferrin: future prospects. Infectious Diseases in Obstetrics and Gynecology 2012, 536037.
52. Ryan C.M., Mehlert A., Richardson J.M., Ferguson M.A., Johnson P.J. Chemical Structure of Trichomonas vaginalis surface lipoglycan: a role for short galactose (β1-4/3) N-acetylglucosamine repeats in host cell interaction. Journal of Biological Chemistry 2011, 286(47):40494-40508.
53. Fichorova R.N., Trifonova R.T., Gilbert R.O., Costello C.E., Hayes G.R., Lucas J.J., et al. Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infection and Immunity 2006, 74(10):5773-5779.
54. Singh B.N., Hayes G.R., Lucas J.J., Sommer U., Viseux N., Mirgorodskaya E., et al. Structural details and composition of Trichomonas vaginalis lipophosphoglycan in relevance to the epithelial immune function. Glycoconjugate Journal 2009, 26(1):3-17.
55. Okumura C.Y., Baum L.G., Johnson P.J. Galectin-1 on cervical epithelial cells is a receptor for the sexually transmitted human parasite Trichomonas vaginalis. Cellular Microbiology 2008, 10(10):2078-2090.
56. Hernandez-Gutierrez R., Avila-Gonzalez L., Ortega-Lopez J., Cruz-Talonia F., Gomez-Gutierrez G., Arroyo R. Trichomonas vaginalis: characterization of a 39-kDa cysteine proteinase found in patient vaginal secretions. Experimental Parasitology 2004, 107(3-4):125-135.
57. Alderete J.F., Provenzano D., Lehker M.W. Iron mediates Trichomonas vaginalis resistance to complement lysis. Microbial Pathogenesis 1995, 19(2):93-103.
58. Hoots B.E., Peterman T.A., Torrone E.A., Weinstock H., Meites E., Bolan G.A. A Trich-y question: should Trichomonas vaginalis infection be reportable?. Sexually Transmitted Diseases 2013, 40(2):113-116.
59. Abraham M.C., Desjardins M., Filion L., Garber G. Inducible immunity to Trichomonas vaginalis in a mouse model of vaginal infection. Infection and Immunity 1996, 64(9):3571-3575.
60. Ravel J., Gajer P., Abdo Z., Schneider G.M., Koenig S.S., McCulle S.L., et al. Vaginal microbiome of reproductive-age women. Proceedings of the National Academy of Sciences 2011, 108(Supp. 1):4680-4687.
61. McGrory T., Garber G.E. Mouse intravaginal infection with Trichomonas vaginalis and role of Lactobacillus acidophilus in sustaining infection. Infection and Immunity 1992, 60(6):2375-2379.
62. Meysick K.C., Garber G.E. Interactions between Trichomonas vaginalis and vaginal flora in a mouse model. Journal of Parasitology 1992, 157-160.
63. Kvasnicka W., Taylor R., Huang J., Hanks D., Tronstad R., Bosomworth A., et al. Investigations of the incidence of bovine trichomoniasis in Nevada and of the efficacy of immunizing cattle with vaccines containing Tritrichomonas foetus. Theriogenology 1989, 31(5):963-971.
64. Kvasnicka W., Hanks D., Huang J., Hall M., Sandblom D., Chu H., et al. Clinical evaluation of the efficacy of inoculating cattle with a vaccine containing Tritrichomonas foetus. American Journal of Veterinary Research 1992, 53(11):2023-2027.
65. Clark B., Dufty J., Parsonson I. Immunisation of bulls against trichomoniasis. Australian Veterinary Journal 1983, 60(6):178-179.
66. Cobo E.R., Corbeil L.B., Gershwin L.J., BonDurant R.H. Preputial cellular and antibody responses of bulls vaccinated and/or challenged with Tritrichomonas foetus. Vaccine 2009, 28(2):361-370.
67. Corbeil L.B., Munson L., Campero C., BonDurant R.H. Bovine trichomoniasis as a model for development of vaccines against sexually-transmitted disease. American Journal of Reproductive Immunology 2001, 45(5):310-319.
68. Corbeil L.B., Campero C.M., Rhyan J., Anderson M., Gershwin L., Agnew D., et al. Uterine mast cells and immunoglobulin-E antibody responses during clearance of Tritrichomonas foetus. Veterinary Pathology Online 2005, 42(3):282-290.
69. Corbeil L.B. Use of an animal model of trichomoniasis as a basis for understanding this disease in women. Clinical Infectious Diseases 1995, 21(Supp. 2):S158-S161.
70. Employment of experimental animals in studies of Trichomonas vaginalis infection. Trichomonads parasitic in humans 1990, 112-154. Springer, New York. J. Kulda, B.M. Honigberg (Eds.).
71. Patton D.L., Sweeney Y.T.C., Agnew K.J., Balkus J.E., Rabe L.K., Hillier S.L. Development of a nonhuman primate model for Trichomonas vaginalis infection. Sexually Transmitted Diseases 2006, 33(12):743-746.
72. Carlton J.M., Hirt R.P., Silva J.C., Delcher A.L., Schatz M., Zhao Q., et al. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science 2007, 315(5809):207-212.
73. Hirt R.P., de Miguel N., Nakjang S., Dessi D., Liu Y.C., Diaz N., et al. Trichomonas vaginalis pathobiology new insights from the genome sequence. Advances in Parasitology 2011, 77:87-140.
74. Meade J.C., Carlton J.M. Genetic diversity in Trichomonas vaginalis. Sexually Transmitted Infections 2013, May. [Published Online First]. 10.1136/sextrans-2013-051098.
75. Hernández H.M., Figueredo M., Garrido N., Sánchez L., Sarracent J. Intranasal immunisation with a 62kDa proteinase combined with cholera toxin or CpG adjuvant protects against Trichomonas vaginalis genital tract infections in mice. International Journal for Parasitology 2005, 35(13):1333-1337.
76. Hernández H.M., Sariego I., Alvarez A.B., Marcet R., Vancol E., Alvarez A., et al. Trichomonas vaginalis 62kDa proteinase as a possible virulence factor. Parasitology Research 2011, 108(1):241-245.
77. Garçon N., Segal L., Tavares F., Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011, 29(27):4453-4459.